<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03551964</url>
  </required_header>
  <id_info>
    <org_study_id>13062017-23-1</org_study_id>
    <secondary_id>2018-002161-19</secondary_id>
    <nct_id>NCT03551964</nct_id>
  </id_info>
  <brief_title>Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction</brief_title>
  <acronym>DAPT-SHOCK-AMI</acronym>
  <official_title>Cangrelor Versus Ticagrelor In Patients With Acute Myocardial Infarction Complicated With Initial Cardiogenic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faculty Hospital Kralovske Vinohrady</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charles University, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Faculty Hospital Kralovske Vinohrady</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter randomized double blind trial comparing intravenous cangrelor and oral ticagrelor
      in patients with acute myocardial infarction complicated by initial cardiogenic shock and
      treated with primary angioplasty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomization to study drugs shall be performed using an online database system for data
      collection; the assigned arm and the randomisation code will be generated after entering
      basic patient data based on a predefined randomization scheme.

      Concomitant therapy. Acetylsalicylic acid - 500 mg i.v. initial dose, and then 100 mg oral
      daily dose. Proton pump inhibitor. Additional therapies including further antithrombotic
      treatment (GP IIb/IIIa inhibitor, heparin) and mechanical support (IABP, ECMO) shall be fully
      in the competence of the treating doctor.

      Electronic database - eCRF. The data from individual follow-up assessments will be entered
      into an electronic database. The online instrument CLADE-IS will be used for data collection;
      this instrument provides robust options for electronic case report form (eCRF) design,
      hierarchical administration of user rights and a user-friendly web interface. The system
      provides predefined validation rules, conversions of variables, and it takes into account the
      relationships between variables; user access is controlled by the hierarchical system of user
      rights and user roles, and database operations are stored for the purpose of audits and
      tracking of changes. Data safety is ensured through physical security of the servers,
      authorised access and backup procedures.

      Laboratory collections. The efficacy of the antiaggregation drugs cangrelor and ticagrelor
      will be determined using the flow cytometry analysis of intracellular VASP
      (vasodilator-stimulated phosphoprotein) phosphorylation.

      Study Committees: Executive c., Steering c., Endpoint adjudication c., Data safety monitoring
      board.

      Monitoring. External monitor Clinical Research Associate (CRA)

      Definitions. Death is defined as death from all causes. Death from cardiovascular causes is
      defined as death with evidence of a cardiovascular cause or any death without clear evidence
      of a non-cardiovascular cause. All deaths are considered as cardiac unless a clear
      non-cardiac cause can be determined. Any unexpected death (for example, even in patients with
      a co-existing, potentially fatal non-cardiac disease - cancer, infection) is classified as a
      death from cardiovascular causes.

      Myocardial reinfarction is defined as a new (additional) MI that must differ from the MI
      based on which the patient was enrolled into the study, satisfying the Third Universal
      Definition of MI criteria.

      Urgent revascularisation of the infarct related artery is defined as a new emergent/urgent
      revascularisation of the artery intervened upon in the initial procedure, due to repeated
      manifestations of ischemia occurring after completion of the initial PCI.

      Stroke is defined as rapid onset of a new neurological deficit due to an ischemic or
      haemorrhagic lesion in the central nervous system with the symptoms lasting for at least 24
      hours from their onset or resulting in death.

      Definitive stent thrombosis is defined according to the Academic Research Consortium
      criteria.

      Bleeding is defined according to the Bleeding Academic Research Consortium (BARC) criteria.

      External collaborating centre for statistical analyses. Institute of Biostatistics and
      Analyses at the Faculty of Medicine of the Masaryk University in Brno, Czech Republic
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical endpoint</measure>
    <time_frame>Within 30 days after randomization</time_frame>
    <description>Combined endpoint defined as Death/Myocardial infarction/Stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory endpoint</measure>
    <time_frame>Periprocedural (periPCI) period</time_frame>
    <description>Early achievement of efficient inhibition of ADP-induced platelet aggregation. Efficient inhibition is defined by the Platelet Reactivity Index (determined based on the VASP protein phosphorylation) &lt; 50%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Key secondary net-clinical endpoint</measure>
    <time_frame>Within 30 days after randomization</time_frame>
    <description>Death/Myocardial infarction/Urgent revascularisation of the infarct-related artery /Stroke/Major bleeding BARC ≥ 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Key safety endpoint</measure>
    <time_frame>Within 30 days after randomization</time_frame>
    <description>Incidence of bleeding according to the BARC definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other secondary endpoint</measure>
    <time_frame>Within 30 days and one year after randomization</time_frame>
    <description>Individual components of the primary clinical endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other secondary endpoint</measure>
    <time_frame>Within 30 days and one year after randomization.</time_frame>
    <description>Death from cardiovascular causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoint</measure>
    <time_frame>Within 30 days after randomization</time_frame>
    <description>Definite stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoint</measure>
    <time_frame>Within 30 days after randomization</time_frame>
    <description>Duration of vasoactive pharmacotherapy and/or mechanical circulatory support (norepinephrine/epinephrine/dopamine in the dose &gt; 5 μg/kg/min/IABP/ECMO),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoint</measure>
    <time_frame>Index event Hospitalization</time_frame>
    <description>Duration of hospitalisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoint</measure>
    <time_frame>Within 30 days after randomization</time_frame>
    <description>Delaying the surgery due to bleeding</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cost analysis</measure>
    <time_frame>Within 30 day after randomization</time_frame>
    <description>Cost-effectiveness analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>MRI sub-study</measure>
    <time_frame>Within one year after randomization</time_frame>
    <description>Magnetic Resonance Imaging sub-study</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">304</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Cardiogenic Shock</condition>
  <arm_group>
    <arm_group_label>Cangrelor therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initiation of iv Cangrelor immediately upon arrival of the patient to the cardiac catheterization laboratory and after randomization into the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initial dose Ticagrelor immediately upon arrival of the patient to the cardiac catheterization laboratory and after randomization into the study. In patients with a disorder of consciousness, initial dose of Ticagrelor will be administered immediately after nasogastric tube insertion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cangrelor</intervention_name>
    <description>Cangrelor: IV bolus 30 μg/kg (application &lt; 1 minute), immediately followed by continuous infusion in the dose of 4 μg/kg/min. To accelerate the initiation of therapy, tables containing calculations of the bolus dose in ml and the speed of infusion therapy for individual weights will be prepared.
Cangrelor therapy will be stopped after circulatory stabilization - when sBP &gt; 100 mmHg persists for one hour / when IABP will be terminated / when vasoactive treatment with norepinephrine, dopamine (in the dose ≥ 5 μg/kg/min) will be stopped, but not later than 4 hours after PCI
30 minutes before stopping Cangrelor infusion, administration of initial dose of crushed Ticagrelor 180 mg and then Ticagrelor maintenance dose 90 mg twice a day for 12 months.</description>
    <arm_group_label>Cangrelor therapy</arm_group_label>
    <other_name>intravenous P2Y12 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Initial dose crushed Ticagrelor 180 mg. Maintenance dose Ticagrelor 90 mg twice daily for 12 months.</description>
    <arm_group_label>Ticagrelor therapy</arm_group_label>
    <other_name>oral P2Y12 inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age over 18 years

          2. Acute myocardial infarction according to the definition of ESC/ACC/AHA, indicated for
             emergency percutaneous coronary intervention (primary PCI strategy)

          3. Cardiogenic shock present upon admission due to the AMI (≥ 2 of the criteria below are
             satisfied)24

               1. sBP &lt; 90 mmHg with the absence of hypovolemia

               2. Need of vasopressor and/or inotropic therapy

               3. Presence of the signs of the organ hypoperfusion - cyanosis, cold acra, disorder
                  of consciousness, congestive heart failure

          4. Informed consent form signed.

        Exclusion Criteria:

          1. Contraindications of antiplatelet therapy with ticagrelor/cangrelor25

               -  Recent (&lt; 6 months) major bleeding

               -  Recent (&lt; 1 month) major surgery/injury

               -  History of intracranial bleeding

               -  History of stroke/TIA

               -  Known intolerance to ticagrelor/cangrelor

               -  Severe impairment of hepatic function

               -  Concomitant administration of strong CYP3A4 inhibitors (for example,
                  ketoconazole, clarithromycin, nefazodone, ritonavir and atazanavir)

          2. Administration of a loading dose of an oral P2Y12 inhibitor prior to admission
             (clopidogrel ≥ 300 mg, ticagrelor 180 mg, prasugrel 60 mg)

          3. Need of concomitant chronic anticoagulation therapy due to indications such as atrial
             fibrillation, artificial valve, thromboembolic disease, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zuzana Motovska, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Kralovske Vinohrady, Prague, Czech Republic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zuzana Motovska, MD. PhD.</last_name>
    <phone>+420731573253</phone>
    <email>motovska.zuzana@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Kralovske Vinohrady</name>
      <address>
        <city>Prague</city>
        <state>Please Select</state>
        <zip>10034</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuzana Motovska, MD PhD</last_name>
      <phone>+420731573253</phone>
      <email>motovska.zuzana@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jiri Knot, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jaroslav Ulman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Anne's University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ota Hlinomaz, MD PhD</last_name>
      <phone>+42054318 5470</phone>
      <email>ota.hlinomaz@fnusa.cz</email>
    </contact>
    <investigator>
      <last_name>Ota Hlinomaz, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology, University Hospital Brno-Bohunice</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Kala, MD. PhD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiology Department, Regional Hospital</name>
      <address>
        <city>Ceske Budejovice</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frantisek Tousek, MD. FESC.</last_name>
    </contact>
    <contact_backup>
      <email>tousek@nemcb.cz</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Hradec Králové</name>
      <address>
        <city>Hradec Králové</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josef Bis, MD PhD</last_name>
      <phone>+420495834239</phone>
      <email>josef.bis@fnhk.cz</email>
    </contact>
    <investigator>
      <last_name>Josef Bis, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jaroslav Dusek, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiology department, Regional hospital</name>
      <address>
        <city>Jihlava</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zdenek Klimsa, MD</last_name>
      <email>klimsaz@nemji.cz</email>
    </contact>
    <contact_backup>
      <last_name>Petr Simek, MD</last_name>
      <email>simekp@nemji.cz</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cardiocenter, Regional Hospital</name>
      <address>
        <city>Karlovy Vary</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Schee, MD</last_name>
    </contact>
    <contact_backup>
      <email>alexandr.schee@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Krajská nemocnice Liberec</name>
      <address>
        <city>Liberec</city>
        <zip>460 63</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiri Karasek, MD</last_name>
      <phone>+420 485 312 646</phone>
      <email>jirikarry@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jiri Karasek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Precek, MD PhD</last_name>
      <phone>+420 588 443 214</phone>
      <email>jan.precek@seznam.cz</email>
    </contact>
    <investigator>
      <last_name>Jan Precek, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Mrozek, MD</last_name>
      <phone>+420 596 920 115</phone>
      <email>honzamrozek@email.cz</email>
    </contact>
    <investigator>
      <last_name>Jan Mrozek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology, Regional Hospital,</name>
      <address>
        <city>Pardubice</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Matejka, MD. PhD.</last_name>
    </contact>
    <contact_backup>
      <email>jan.matejka@nempk.cz</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Pilsen</name>
      <address>
        <city>Pilsen</city>
        <zip>304 60</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milan Hromadka, MD PhD</last_name>
      <phone>+00420377 103 3166</phone>
      <email>hromadka@fnplzen.cz</email>
    </contact>
    <investigator>
      <last_name>Milan Hromadka, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General University Hospital in Prague</name>
      <address>
        <city>Prague</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana Smalcova, MD</last_name>
      <phone>+420224962504</phone>
      <email>jana.smalcova@vfn.cz</email>
    </contact>
    <investigator>
      <last_name>Jana Smalcova, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Belohlavek, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tomas Kovarnik, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Clinical and Experimental Medicine</name>
      <address>
        <city>Prague</city>
        <zip>14021</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiri Kettner, MD CSc</last_name>
      <phone>+42023 605 5007</phone>
      <email>jiri.kettner@ikem.cz</email>
    </contact>
    <investigator>
      <last_name>Jiri Kettner, MD CSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <zip>150 30</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Ostadal, MD PhD</last_name>
      <phone>+420 257 272 208</phone>
      <email>petr.ostadal@homolka.cz</email>
    </contact>
    <investigator>
      <last_name>Petr Ostadal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiocenter, Hospital Podlesi</name>
      <address>
        <city>Trinec</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Libor Sknouril, MD. PhD.</last_name>
    </contact>
    <contact_backup>
      <email>libor.sknouril@nempodlesi.cz</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Regional Hospital T. Bati</name>
      <address>
        <city>Zlin</city>
        <zip>762 75</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zdenek Coufal, MD</last_name>
      <phone>+420577 552 138</phone>
      <email>coufal@bnzlin.cz</email>
    </contact>
    <investigator>
      <last_name>Zdenek Coufal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Griva, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Masaryk Hospital</name>
      <address>
        <city>Ústí Nad Labem</city>
        <zip>40011</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Cervinka, MD PhD</last_name>
      <phone>+420 477 117 886</phone>
      <email>pavel.cervinka@kzcr.eu</email>
    </contact>
    <investigator>
      <last_name>Pavel Cervinka, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vladimir Hrabos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Middle-Slovak Institute of Cardiovascular Diseases</name>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Hudec, MD. PhD.</last_name>
      <email>hudec@suscch.eu</email>
    </contact>
    <investigator>
      <last_name>Marek Strachan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center of Interventional Neuroradiology and Endovascular Treatment</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Vulev, MD. MPH, FCIRSE</last_name>
      <email>ivan.vulev@cinre.sk</email>
    </contact>
    <contact_backup>
      <last_name>David Líška, MD</last_name>
      <email>david.liska@cinre.sk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cardiocentre</name>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Obona, MD</last_name>
      <email>pobona@centrum.sk</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Andrasova, MD</last_name>
      <email>andrea.andrasova@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 29, 2018</study_first_submitted>
  <study_first_submitted_qc>June 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2018</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Faculty Hospital Kralovske Vinohrady</investigator_affiliation>
    <investigator_full_name>Zuzana Motovska</investigator_full_name>
    <investigator_title>Zuzana Motovska MD PHD</investigator_title>
  </responsible_party>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>Cardiogenic shock</keyword>
  <keyword>Primary percutaneous coronary intervention</keyword>
  <keyword>Dual antiplatelet therapy</keyword>
  <keyword>Cangrelor</keyword>
  <keyword>Ticagrelor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Cangrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

